Breast cancer Posts on Medivizor
Navigation Menu

Breast cancer Posts on Medivizor

Comparing the frequency and severity of nerve disease with eribulin versus paclitaxel before surgery in women with breast cancer

Comparing the frequency and severity of nerve disease with eribulin versus paclitaxel before surgery in women with breast cancer

Posted by on Jan 15, 2023 in Breast cancer | 0 comments

In a nutshell The study compared the frequency and severity of neuropathy (nerve damage) eribulin (Halaven) with paclitaxel (Taxol) given before surgery in women with operable breast cancer (BC). The study found that the frequency and severity of neuropathy were reduced in patients who received eribulin than in patients who received...

Read More

Evaluating the optimal treatment regimens given before and after surgery in improving survival outcomes in patients with HER2-positive breast cancer.

Evaluating the optimal treatment regimens given before and after surgery in improving survival outcomes in patients with HER2-positive breast cancer.

Posted by on Jan 8, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the optimal treatment regimens given before and after surgery in terms of improving the survival outcomes in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC). The data showed that chemotherapy plus trastuzumab (Herceptin) and pertuzumab (Perjeta) was the best treatment...

Read More

Evaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2– metastatic breast cancer resistant to hormone therapy.

Evaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2– metastatic breast cancer resistant to hormone therapy.

Posted by on Jan 8, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of abemaciclib (Verzenio) alone or in combination with tamoxifen (Nolvadex) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC) resistant to hormone therapy. The data showed that abemaciclib in combination with tamoxifen was more effective in improving...

Read More

Comparing the effectiveness and safety of combined therapy of atezolizumab with nab-paclitaxel in patients with triple negative breast cancer

Comparing the effectiveness and safety of combined therapy of atezolizumab with nab-paclitaxel in patients with triple negative breast cancer

Posted by on Jan 3, 2023 in Breast cancer | 0 comments

In a nutshell The study compared the effectiveness and safety of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) combined therapy with nab-paclitaxel alone in patients with triple-negative breast cancer (TNBC). The study found that combined therapy was more effective than single therapy but it had more serious side effects in these...

Read More

Evaluating the effectiveness of massage therapy for chemotherapy-induced nerve disease

Evaluating the effectiveness of massage therapy for chemotherapy-induced nerve disease

Posted by on Jan 3, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the effectiveness of massage therapy for chemotherapy-induced peripheral neuropathy (CIPN) in patients with breast and gastrointestinal (GI) cancer. The main finding of the study was that intensive massage therapy 3 times a week showed promising results in these patients.  Some background There are many...

Read More

Evaluating the effectiveness of fulvestrant plus capivasertib in patients with aromatase inhibitor-resistant estrogen receptor-positive, HER2-negative advanced breast cancer.

Evaluating the effectiveness of fulvestrant plus capivasertib in patients with aromatase inhibitor-resistant estrogen receptor-positive, HER2-negative advanced breast cancer.

Posted by on Dec 30, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of fulvestrant (Faslodex) plus capivasertib (AZD5363) in patients with aromatase inhibitor-resistant estrogen receptor-positive (ER+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that fulvestrant plus capivasertib significantly improved the survival outcomes in these...

Read More

Comparing the safety of palbociclib combined with fulvestrant or letrozole in HR+/HER2- advanced breast cancer

Comparing the safety of palbociclib combined with fulvestrant or letrozole in HR+/HER2- advanced breast cancer

Posted by on Dec 30, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the safety profile of palbociclib (Ibrance) combined with either fulvestrant (Faslodex) or letrozole (Femara) in patients with hormone-receptor-positive (HR+) and HER2 negative (HER2 -) advanced breast cancer (BC). The data showed that both palbociclib regimens were safe and tolerated in these patients with some...

Read More

Comparing the effectiveness and safety of combined therapy of pertuzumab with trastuzumab versus single trastuzumab therapy in patients with HER2-positive advanced breast cancer

Comparing the effectiveness and safety of combined therapy of pertuzumab with trastuzumab versus single trastuzumab therapy in patients with HER2-positive advanced breast cancer

Posted by on Nov 14, 2022 in Breast cancer | 0 comments

In a nutshell The study compared the effectiveness and safety of pertuzumab (Perjeta) and trastuzumab (Herceptin) combined therapy with trastuzumab alone in patients with HER2-positive (HER2+) advanced breast cancer (BC). The study found that the combined therapy was more effective and well tolerated compared to single therapy in...

Read More

Evaluating the effectiveness and safety of elacestrant versus standard hormonal therapy in patients with ER+/HER2- advanced BC.

Evaluating the effectiveness and safety of elacestrant versus standard hormonal therapy in patients with ER+/HER2- advanced BC.

Posted by on Oct 7, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of elacestrant (RAD1901) versus standard hormonal therapy in patients with estrogen receptor-positive (ER+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that elacestrant significantly improved survival without cancer worsening with manageable side effects in these...

Read More

Evaluating the long-term effectiveness and safety of palbociclib plus fulvestrant treatment in patients with HR+/HER2- advanced BC.

Evaluating the long-term effectiveness and safety of palbociclib plus fulvestrant treatment in patients with HR+/HER2- advanced BC.

Posted by on Sep 18, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of palbociclib (Ibrance) plus fulvestrant (Faslodex) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding palbociclib to fulvestrant was safe and significantly improved the overall survival over the...

Read More

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Posted by on Sep 1, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...

Read More